Wilson W R
Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA.
Diagn Microbiol Infect Dis. 1998 Jul;31(3):473-7. doi: 10.1016/s0732-8893(98)00041-8.
For many years, the third-generation cephalosporins have been utilized in the treatment of a broad range of infections. The reduction in the efficacy of these antimicrobials in hospitals seen in recent years is a result of the development of resistance to these compounds. This resistance, caused in part by the production of beta-lactamases which can spread from species to species, has intensified the search for alternative agents. Compared with third-generation cephalosporins, fourth-generation cephalosporins possess enhanced activity against Gram-positive organisms, excellent penetration into Gram-negative bacilli, and are more stable against the activity of some beta-lactamases. Accordingly, fourth-generation cephalosporins are attractive candidates to replace third-generation cephalosporins for the treatment of many nosocomial infections.
多年来,第三代头孢菌素一直用于治疗多种感染。近年来在医院中这些抗菌药物疗效的降低是对这些化合物产生耐药性的结果。这种耐药性部分是由可在物种间传播的β-内酰胺酶的产生引起的,这加剧了对替代药物的寻找。与第三代头孢菌素相比,第四代头孢菌素对革兰氏阳性菌具有增强的活性,对革兰氏阴性杆菌具有出色的穿透力,并且对某些β-内酰胺酶的活性更稳定。因此,第四代头孢菌素是替代第三代头孢菌素治疗许多医院感染的有吸引力的候选药物。